Cargando…

Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis

Although adoptive immunotherapy (AIT) is a novel emerging target treatment for non-small cell lung cancer (NSCLC), its actual efficacy remains controversial. In this meta-analysis, we aimed to evaluate the efficacy of AIT for NSCLC. We systematically searched PubMed, the Cochrane Library, EMBASE, Me...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Binghao, Zhang, Wenxiong, Yu, Dongliang, Xu, Jianjun, Wei, Yiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762575/
https://www.ncbi.nlm.nih.gov/pubmed/29348890
http://dx.doi.org/10.18632/oncotarget.19373
_version_ 1783291713778876416
author Zhao, Binghao
Zhang, Wenxiong
Yu, Dongliang
Xu, Jianjun
Wei, Yiping
author_facet Zhao, Binghao
Zhang, Wenxiong
Yu, Dongliang
Xu, Jianjun
Wei, Yiping
author_sort Zhao, Binghao
collection PubMed
description Although adoptive immunotherapy (AIT) is a novel emerging target treatment for non-small cell lung cancer (NSCLC), its actual efficacy remains controversial. In this meta-analysis, we aimed to evaluate the efficacy of AIT for NSCLC. We systematically searched PubMed, the Cochrane Library, EMBASE, Medline, and Web of Science for relevant parallel randomized controlled trials (RCTs) and high-quality observation studies of AIT without any language restrictions. Two investigators reviewed all the texts and extracted information regarding overall survival rate (OS), progression-free survival rate (PFS), objective response rate (ORR), and disease control rate (DCR) from eligible studies; sensitivity analyses and subgroup analyses were also conducted to reduce heterogeneity Of 319 suitable studies, 15 studies (13 RCTs and 2 observation studies) involving 1684 patients were finally included. Compared to the Control therapy (CT) group, the AIT group exhibited better 1-year OS (P = 0.001), 2-year OS (P < 0.001), 3-year OS (P < 0.001), 5-year OS (P = 0.032), 1-year PFS (P < 0.001), and 2-year PFS (P = 0.029). The difference in the ORR (P = 0.293) and DCR (P = 0.123) was not significant between the groups. The subgroup analysis showed that DC/CIK did more benefit to NSCLC patients than LAK and the cycles not associated with AIT efficacy. AIT can significantly improve the OS and PFS with acceptable toxicity for NSCLC. Nevertheless, further multicenter studies are needed to confirm our conclusion and determine which adoptive immunotherapy is associated with the greatest efficacy.
format Online
Article
Text
id pubmed-5762575
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-57625752018-01-18 Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis Zhao, Binghao Zhang, Wenxiong Yu, Dongliang Xu, Jianjun Wei, Yiping Oncotarget Meta-Analysis Although adoptive immunotherapy (AIT) is a novel emerging target treatment for non-small cell lung cancer (NSCLC), its actual efficacy remains controversial. In this meta-analysis, we aimed to evaluate the efficacy of AIT for NSCLC. We systematically searched PubMed, the Cochrane Library, EMBASE, Medline, and Web of Science for relevant parallel randomized controlled trials (RCTs) and high-quality observation studies of AIT without any language restrictions. Two investigators reviewed all the texts and extracted information regarding overall survival rate (OS), progression-free survival rate (PFS), objective response rate (ORR), and disease control rate (DCR) from eligible studies; sensitivity analyses and subgroup analyses were also conducted to reduce heterogeneity Of 319 suitable studies, 15 studies (13 RCTs and 2 observation studies) involving 1684 patients were finally included. Compared to the Control therapy (CT) group, the AIT group exhibited better 1-year OS (P = 0.001), 2-year OS (P < 0.001), 3-year OS (P < 0.001), 5-year OS (P = 0.032), 1-year PFS (P < 0.001), and 2-year PFS (P = 0.029). The difference in the ORR (P = 0.293) and DCR (P = 0.123) was not significant between the groups. The subgroup analysis showed that DC/CIK did more benefit to NSCLC patients than LAK and the cycles not associated with AIT efficacy. AIT can significantly improve the OS and PFS with acceptable toxicity for NSCLC. Nevertheless, further multicenter studies are needed to confirm our conclusion and determine which adoptive immunotherapy is associated with the greatest efficacy. Impact Journals LLC 2017-07-19 /pmc/articles/PMC5762575/ /pubmed/29348890 http://dx.doi.org/10.18632/oncotarget.19373 Text en Copyright: © 2017 Zhao et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Meta-Analysis
Zhao, Binghao
Zhang, Wenxiong
Yu, Dongliang
Xu, Jianjun
Wei, Yiping
Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis
title Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis
title_full Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis
title_fullStr Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis
title_full_unstemmed Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis
title_short Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis
title_sort adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis
topic Meta-Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762575/
https://www.ncbi.nlm.nih.gov/pubmed/29348890
http://dx.doi.org/10.18632/oncotarget.19373
work_keys_str_mv AT zhaobinghao adoptiveimmunotherapyshowsencouragingbenefitonnonsmallcelllungcancerasystematicreviewandmetaanalysis
AT zhangwenxiong adoptiveimmunotherapyshowsencouragingbenefitonnonsmallcelllungcancerasystematicreviewandmetaanalysis
AT yudongliang adoptiveimmunotherapyshowsencouragingbenefitonnonsmallcelllungcancerasystematicreviewandmetaanalysis
AT xujianjun adoptiveimmunotherapyshowsencouragingbenefitonnonsmallcelllungcancerasystematicreviewandmetaanalysis
AT weiyiping adoptiveimmunotherapyshowsencouragingbenefitonnonsmallcelllungcancerasystematicreviewandmetaanalysis